You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019020
Jan 2020041
Feb 2020052
Mar 2020003
Apr 2020010
May 2020031
Jun 2020041
Jul 2020021
Aug 2020020
Sep 2020051
Oct 2020001
Nov 2020030
Dec 2020011
Jan 2021031
Feb 2021002
Mar 2021010
Apr 2021031
May 2021011
Jun 2021001
Jul 2021028
Aug 2021011
Sep 2021024
Oct 20210318
Nov 20210314
Dec 2021060
Jan 2022032
Feb 2022041
Mar 2022031
Apr 2022021
May 2022057
Jun 2022032
Jul 2022041
Aug 2022032
Sep 2022033
Oct 2022035
Nov 20220162
Dec 2022060
Jan 2023072
Feb 2023021
Mar 2023010
Apr 2023010
May 2023002
Jun 2023010
Jul 2023015
Aug 2023001
Sep 2023033
Oct 2023022
Nov 2023043
Dec 2023061
Jan 2024030
Feb 2024095
Mar 20240637
Total0158152